Tenofovir interruption among people with HIV and HBV: HBV monitoring and risk of HBV reactivation and hepatitis flare.

ABSTRACT:

Objective

To assess HBV monitoring, HBV reactivation and hepatitis flares during tenofovir interruptions among people with HIV and HBV.

Design

Cohort study of electronic health records.

Methods

All tenofovir (tenofovir disoproxil fumarate, tenofovir alafenamide) interruptions among people with HIV and positive HBV surface antigen (HBsAg) or positive HBV core antibody (HBcAb) were categorized by reactivation risk (high: HBsAg+; moderate: HBsAg-/HBcAb+/surface antibody [HBsAb] negative; low: HBsAg-/HBcAb+/HBsAb+). Incidence rates of HBV reactivation and hepatitis flare were assessed with Poisson regression.

Results

Among 5343 individuals with HIV and HBV, there were 6252 tenofovir interruptions (11% high-, 19% moderate-, 69% low-risk). During the interruptions, H

SUBMITTER: Dieterich DT 

PROVIDER: S-EPMC12700698 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature